Figure 6: Anti-PD1 boosts Trm-like cells in the tumour after Tcm transfer.

(a,b) Untreated mice or mice injected i.d. with B16-OVA (a) or s.c. with MC38-OVA (b) were transferred with OT-I Tcm cells. Expression of PD-1 in OT-I cells was analysed 7 days later in draining LNs (dLN) or tumours. (c) Mice were injected with the indicated tumours, transferred i.v. with OT-I CD45.1⁺ Tcm cells, and treated with anti-PD-1. (d,e) tumour weight at the time of killing following B16-OVA (d) or MC38-OVA (e) inoculation. (f,g) Frequency (top) and numbers (bottom) of OT-I CD69⁺ infiltrating B16-OVA (f) or MC38-OVA (g) tumours in mice treated as indicated (c). Pool of four (d) and three (a,b,e–g) independent experiments represented as individual points and mean±s.e.m. (a,b) (n=2–3 per control group, 3–4 per tumour group), (d–g) (n=3–5 per group). NS, not significant, ***P<0.001; **P<0.01; *P<0.05 by one-way ANOVA (a,b) with Bonferroni post-hoc test, two-tailed unpaired Student’s t-test (f top) and two-tailed nonparametric Mann–Whitney test (d-f bottom, g).